PTGS2 and neoplasm: Selective COX-2 inhibitors have been shown to be active as tumor chemopreventive agents in preclinical models as well as in humans [15,17,18], and to enhance the cytotoxicity exerted in vitro by different chemotherapeutics, including platinating agents [19,20].